Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ( E8 [; J- I W/ t- _ P" y" N
. e; g3 q! d% `5 h
& q0 z' Y2 n. S% q( V& lSub-category:# E8 ^" `4 T! F* o
Molecular Targets
- w& J& ?$ F3 ^( a
3 B/ a) E9 J% O2 Y- X9 |' j
9 J O, }% T* CCategory:- X" `4 E0 L- O: O7 B, w. G
Tumor Biology
# Q4 m& U% e; R" i( Y9 k P9 I) F( Q9 E& }7 w; E3 D: y2 \: g
& y% m% N# m% G4 U
Meeting:: ^* ^8 V/ k% M' X3 p, l4 K: m
2011 ASCO Annual Meeting ) s; u' @: }. |9 w3 H9 W/ `
& x! n ] v1 O% W- q. w# v& ~, }3 B$ K
Session Type and Session Title:0 A( Y& U- W# k' K, o s5 n* T
Poster Discussion Session, Tumor Biology
. n9 G2 {$ B! D7 o3 y) V( H" I& {& [" Q4 E5 i5 L( @6 ~
4 d9 Y) s: V) N# ]" ?% N
Abstract No:
$ O' e0 n* n! G! H% B10517 : V* R3 ]# c4 e( l
: R _) K3 _% b, w
0 O2 K3 x, C! B" L: L0 s
Citation:& V j, x% O* y" m
J Clin Oncol 29: 2011 (suppl; abstr 10517) . |7 B; ?3 q+ A) }* v
6 T( e, M& t$ Q4 j
1 Q3 Q6 y) v6 y: L2 b e
Author(s):
p6 }) i; U( S" A6 k- H$ b& w, fJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 F$ k Z9 F/ D
9 j$ a* k$ C# w5 V% n" c0 s
- j$ j4 T# m2 r2 j" N$ u; M
+ O" z) J" N$ M# QAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings./ z7 H* L( X: m0 R% l: b ^" D+ O
- z1 a9 y! {6 } t! kAbstract Disclosures
' }# J( @& _6 @ W/ ?: E* l+ l6 q$ A: O: \
Abstract:7 K7 p ]2 i8 @
3 g0 ?" V6 v; Z* g8 A7 N
' _9 V5 P o) I" wBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.8 u# M" C9 h# m
+ ?6 _9 h- U- T; u4 g* |
1 A, F$ O3 L! n! E4 K. C4 H |
显身卡
